

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	3	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	4	MAR 31	CA/Caplus and CASREACT patent number format for U.S. applications updated
NEWS	5	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	6	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	7	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	8	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	9	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	10	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	11	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	12	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	13	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	14	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	15	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	16	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	17	JUN 25	CA/Caplus and USPAT databases updated with IPC reclassification data
NEWS	18	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	19	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	20	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	21	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS	22	JUL 28	CA/Caplus patent coverage enhanced
NEWS	23	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS	24	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	25	JUL 28	STN Viewer performance improved
NEWS EXPRESS	JUNE 27 08	CURRENT WINDOWS VERSION IS V8.3,	
		AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.	
NEWS HOURS		STN Operating Hours Plus Help Desk Availability	
NEWS LOGIN		Welcome Banner and News Items	
NEWS IPC8		For general information regarding STN implementation of IPC 8	

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 12:09:34 ON 29 JUL 2008

```
=> file reg
COST IN U.S. DOLLARS                SINCE FILE      TOTAL
                                     ENTRY      SESSION
FULL ESTIMATED COST                0.21          0.21
```

FILE 'REGISTRY' ENTERED AT 12:09:46 ON 29 JUL 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 JUL 2008 HIGHEST RN 1036756-19-0  
DICTIONARY FILE UPDATES: 28 JUL 2008 HIGHEST RN 1036756-19-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>


=>  
Uploading C:\Program Files\Stnexp\Queries\10566101.str



chain nodes :  
10 11 12 14 15 18 19  
ring nodes :  
1 2 3 4 5 6 7 8 9  
chain bonds :

```
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 14:CLASS 15:CLASS 18:Atom 19:CLASS
```

```
=> d l1
L1 HAS NO ANSWERS
L1 STR
```



```
=> s ll full
FULL SEARCH INITIATED 12:10:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      423 TO ITERATE
```

```
=> file caplus
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                                ENTRY      SESSION
FULL ESTIMATED COST          178.36      178.57
```

FILE 'CAPLUS' ENTERED AT 12:10:08 ON 29 JUL 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Jul 2008 VOL 149 ISS 5  
FILE LAST UPDATED: 28 Jul 2008 (20080728/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l3 full

L3 NOT FOUND

The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l2 full

L3 4 L2

=> d ibib abs hitstr tot

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:136598 CAPLUS

DOCUMENT NUMBER: 142:240323

TITLE: Active substance combination comprising a compound with NPY receptor affinity and a compound with 5-HT6 receptor affinity

INVENTOR(S): Torrens Jover, Antoni; Mas Prio, Josep; Dordal Zueras, Alberto; Codony Soler, Xavier; Merce Vidal, Ramon; Aurelio Castrillo Perez, Jose; Frigola Constansa, Jordi; Buschmann, Helmut-Heinrich

PATENT ASSIGNEE(S): Laboratorios del Esteve S. A., Spain

SOURCE: PCT Int. Appl., 427 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005014045	A1	20050217	WO 2004-EP8514	20040729
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2228268	A1	20050401	ES 2003-1815	20030730
ES 2228268	B1	20060701		
AU 2004262488	A1	20050217	AU 2004-262488	20040729
CA 2534099	A1	20050217	CA 2004-2534099	20040729
EP 1660131	A1	20060531	EP 2004-741321	20040729
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
IN 2005DN06119	A	20080711	IN 2005-DN6119	20051228
MX 2006PA01230	A	20060515	MX 2006-PA1230	20060130
US 20070009597	A1	20070111	US 2006-566402	20060705
PRIORITY APPLN. INFO.:			ES 2003-1815	A 20030730
			WO 2004-EP8514	W 20040729
OTHER SOURCE(S):		CASREACT 142:240323; MARPAT 142:240323		
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The present invention relates to an active substance combination comprising at least one compound I [R1-R4 = H, halo, alkyl, etc.; R5 = H, alkyl, (un)saturated cycloalkyl; R6-R9 = H, alkyl, (un)saturated cycloalkyl, etc.;

A = CHR18, CHR18CH2; B = alkyl, (un)saturated cycloalkyl, etc.; R10 = H, alkyl, (un)saturated cycloalkyl, etc.; R11 = alkyl, (un)saturated cycloalkyl, etc.; NR10R11 = (un)saturated heterocyclyl; R18 = H, alkyl, (un)saturated cycloalkyl, etc.] with neuropeptide Y-receptor affinity, preferably neuropeptide Y5-receptor affinity, and at least one compound with 5-HT6 receptor affinity (such as II [R1 = H, alkyl, Ph, CH2PH; R2 = NR4R5,

(un)saturated (hetero)cycloalkyl, etc.; R3 = H, alkyl; R4, R5 = H, alkyl; or NR4R5 = (un)saturated heterocyclyl; A = (un)substituted (hetero)aryl; n = 0-4)), a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament. Synthesis of amides I and sulfonamides such as II is described in examples. E.g., a multi-step synthesis of III.HCl, starting from 1-(tert-butoxycarbonyl)-4-piperidinone and Me anthranilate, was given. The amides I and sulfonamides such as II were tested against neuropeptide Y5 and 5-HT6 binding (data given for representative compds.).


IT 753020-88-1P 753020-90-5P 753020-91-6P  
844477-59-4P 844477-64-1P 844477-68-5P  
844477-70-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amides and sulfonamides as components of active combination with NPY receptor affinity and 5-HT6 receptor affinity)


RN 753020-88-1 CAPLUS

CN Imidazo[2,1-b]thiazole-5-sulfonamide, 6-chloro-N-[1-[2-(dimethylamino)ethyl]-1H-indol-6-yl]- (CA INDEX NAME)




RN 753020-90-5 CAPLUS

CN 1-Naphthalenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-6-yl]- (CA INDEX NAME)




RN 753020-91-6 CAPLUS

CN 2-Naphthalenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-6-yl]- (CA INDEX NAME)




RN 844477-59-4 CAPLUS


CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-N-[1-[2-(dimethylamino)ethyl]-1H-indol-6-yl]-3-methyl- (CA INDEX NAME)




RN 844477-64-1 CAPLUS  
 CN [1,1'-Biphenyl]-4-sulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-6-yl]- (CA INDEX NAME)



RN 844477-68-5 CAPLUS  
 CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-6-yl]-4-phenoxy- (CA INDEX NAME)



RN 844477-70-9 CAPLUS  
 CN Benzenesulfonamide, 3,5-dichloro-N-[1-[2-(dimethylamino)ethyl]-1H-indol-6-yl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:136568 CAPLUS

DOCUMENT NUMBER: 142:240322

TITLE: Active substance combination comprising a compound with NPY receptor affinity and a compound with 5-HT6 receptor affinity

INVENTOR(S): Torrens Jover, Antoni; Mas Prio, Josep; Dordal Zueras, Alberto; Codony Soler, Xavier; Merce Vidal, Ramon; Aurelio Castrillo Perez, Jose; Frigola Constansa, Jordi; Buschmann, Helmut-Heinrich

PATENT ASSIGNEE(S): Laboratorios del Esteve S. A., Spain

SOURCE: PCT Int. Appl., 451 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005014000	A1	20050217	WO 2004-EP8515	20040729
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
ES 2228267	A1	20050401	ES 2003-1814	20030730
ES 2228267	B1	20060701		
AU 2004262489	A1	20050217	AU 2004-262489	20040729
CA 2534100	A1	20050217	CA 2004-2534100	20040729
EP 1648468	A1	20060426	EP 2004-763612	20040729
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
IN 2005DN06118	A	20080711	IN 2005-DN6118	20051228
MX 2006PA01232	A	20060515	MX 2006-PA1232	20060130
US 20070059364	A1	20070315	US 2006-566100	20061026
PRIORITY APPLN. INFO.:			ES 2003-1814	A 20030730
			WO 2004-EP8515	W 20040729
OTHER SOURCE(S):	MARPAT 142:240322			
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The present invention relates to an active substance combination comprising at least one compound I [R1-R4 = H, halo, alkyl, etc.; R5 = H, alkyl, (un)saturated (hetero)cycloalkyl; R6-R9 = H, alkyl, (un)saturated (hetero)cycloalkyl, etc.; A = CHR18, CHR18CH2; R10 = H, alkyl, (un)saturated cycloalkyl, etc.; R11 = alkyl, (un)saturated cycloalkyl, etc.; NR10R11 = (un)saturated heterocyclyl; R18 = H, alkyl, (un)saturated cycloalkyl, etc.] with neuropeptide Y-receptor affinity, preferably neuropeptide Y5-receptor affinity, and at least one compound with 5-HT6 receptor affinity (such as II [R1 = H, alkyl, Ph, CH2PH; R2 = NR4R5, (un)saturated (hetero)cycloalkyl, etc.;



R3 = H, alkyl; R4, R5 = H, alkyl; or NR4R5 = (un)saturated heterocyclyl; A = (un)substituted (hetero)aryl; n = 0-4)), a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament. Synthesis of amides I and sulfonamides such as II is described in examples. Thus, reacting 6-chloro-1-(4-piperidinyl)-1,4-dihydro-2H-3,1-benzoxazinone hydrochloride with 2-(2-chloroacetamide)-2',5-dichlorobenzophenone in the presence of K2CO3 in DMF followed by treating of the free base with HCl/EtOH afforded 61% III.HCl. The amides I and sulfonamides such as II were tested against neuropeptide Y5 and 5-HT6 binding (data given for representative compds.).


IT 753020-88-1P 753020-90-5P 753020-91-6P  
844477-59-4P 844477-64-1P 844477-68-5P  
844477-70-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amides and sulfonamides as components of active combination with NPY receptor affinity and 5-HT6 receptor affinity)


RN 753020-88-1 CAPLUS

CN Imidazo[2,1-b]thiazole-5-sulfonamide, 6-chloro-N-[1-[2-(dimethylamino)ethyl]-1H-indol-6-yl]- (CA INDEX NAME)




RN 753020-90-5 CAPLUS

CN 1-Naphthalenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-6-yl]- (CA INDEX NAME)




RN 753020-91-6 CAPLUS

CN 2-Naphthalenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-6-yl]- (CA INDEX NAME)




RN 844477-59-4 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-N-[1-[2-(dimethylamino)ethyl]-1H-indol-6-yl]-3-methyl- (CA INDEX NAME)




RN 844477-64-1 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-6-yl]- (CA INDEX NAME)




RN 844477-68-5 CAPLUS

CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-6-yl]-4-phenoxy- (CA INDEX NAME)



RN 844477-70-9 CAPLUS

CN Benzenesulfonamide, 3,5-dichloro-N-[1-[2-(dimethylamino)ethyl]-1H-indol-6-yl]- (CA INDEX NAME)




REFERENCE COUNT:

5


THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2005:136548 CAPLUS  
 DOCUMENT NUMBER: 142:240309  
 TITLE: Preparation of indol-6-ylsulfonamide derivatives and their use as 5-HT6 modulators  
 INVENTOR(S): Merce Vidal, Ramon; Codony Soler, Xavier; Dordal Zuera, Alberto  
 PATENT ASSIGNEE(S): Laboratorios del Esteve S. A., Spain  
 SOURCE: PCT Int. Appl., 92 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005013976	A1	20050217	WO 2004-EP8510	20040729
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2222832	A1	20050201	ES 2003-1810	20030730
ES 2222832	B1	20060216		
AU 2004262484	A1	20050217	AU 2004-262484	20040729
CA 2533970	A1	20050217	CA 2004-2533970	20040729
EP 1660077	A1	20060531	EP 2004-741319	20040729
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1832738	A	20060913	CN 2004-80022271	20040729
BR 2004013112	A	20061003	BR 2004-13112	20040729
JP 2007500164	T	20070111	JP 2006-521528	20040729
NZ 545301	A	20080530	NZ 2004-545301	20040729
MX 2006PA01141	A	20060424	MX 2006-PA1141	20060127
NO 2006000682	A	20060210	NO 2006-682	20060210
US 20070043041	A1	20070222	US 2006-566101	20060810
PRIORITY APPLN. INFO.:			ES 2003-1810	A 20030730
			WO 2004-EP8510	W 20040729
OTHER SOURCE(S):		CASREACT 142:240309; MARPAT 142:240309		
GI				



I



II

AB Title compds. I [R1 = NR8R9 radical or a (un)saturated, optionally at least monosubstituted cycloaliph. radical which may contain at least one heteroatom; R2-5,7 independently = H, halo, NO2, alkoxy, etc.; R6 = H or (un)saturated aliphatic radical optionally at least monosubstituted; R8 and R9

= H or (un)saturated aliphatic radical optionally at least monosubstituted with provisions, or R8 and R9 together with the N atom form a (un)saturated heterocyclic ring optionally at least monosubstituted; A = mono or polycyclic aromatic ring system which may be bonded via (un)substituted alkylene, alkenylene or alkynylene group; n = 0-4], and their pharmaceutically acceptable salts, are prepared and disclosed as useful for medicaments in human and/or veterinary therapeutics for diseases/disorders related to 5-HT6 receptor. Thus, e.g., II was prepared by the reaction of 5-chloro-3-methylbenzo[b]thiophene-2-sulfonyl chloride with 6-amino-1-(2-dimethylaminoethyl)-1H-indole. Selected compds. of the invention were evaluated for binding with 5-HT6 receptor; % inhibition values reported to range from 86.9-98.6 at 10-6M concns.


IT 753020-88-1P 753020-90-5P 753020-91-6P  
844477-59-4P 844477-64-1P 844477-68-5P  
844477-70-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of indol-6-ylsulfonamide derivs. as 5-HT6 receptor modulators)

RN 753020-88-1 CAPLUS


CN Imidazo[2,1-b]thiazole-5-sulfonamide, 6-chloro-N-[1-[2-(dimethylamino)ethyl]-1H-indol-6-yl]- (CA INDEX NAME)



RN 753020-90-5 CAPLUS


CN 1-Naphthalenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-6-yl]-

(CA INDEX NAME)




RN 753020-91-6 CAPLUS

CN 2-Naphthalenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-6-yl]-  
(CA INDEX NAME)




RN 844477-59-4 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-N-[1-[2-(dimethylamino)ethyl]-1H-indol-6-yl]-3-methyl- (CA INDEX NAME)




RN 844477-64-1 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-6-yl]- (CA INDEX NAME)




RN 844477-68-5 CAPLUS

CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-6-yl]-4-phenoxy-  
(CA INDEX NAME)



RN 844477-70-9 CAPLUS

CN Benzenesulfonamide, 3,5-dichloro-N-[1-[2-(dimethylamino)ethyl]-1H-indol-6-yl]- (CA INDEX NAME)



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:725572 CAPLUS

DOCUMENT NUMBER: 142:211383

TITLE: Medicinal Chemistry Driven Approaches Toward Novel and Selective Serotonin 5-HT<sub>6</sub> Receptor Ligands

AUTHOR(S): Holenz, Joerg; Merce, Ramon; Diaz, Jose Luis; Guitart, Xavier; Codony, Xavier; Dordal, Alberto; Romero, Gonzalo; Torrens, Antoni; Mas, Josep; Andaluz, Blas; Hernandez, Susana; Monroy, Xavier; Sanchez, Elisabeth; Hernandez, Enrique; Perez, Raquel; Cubi, Roger; Sanfeliu, Olga; Buschmann, Helmut

CORPORATE SOURCE: Departments of Medicinal Chemistry, Discovery Biology and Discovery Chemistry, Laboratorios Dr. Esteve S.A., Barcelona, 08041, Spain

SOURCE: Journal of Medicinal Chemistry (2005), 48(6), 1781-1795

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:211383

AB Based on a medicinal chemical guided hypothetical pharmacophore model, novel series of indolyl sulfonamides have been designed and prepared as selective and high-affinity serotonin 5-HT<sub>6</sub> receptor ligands. Furthermore, based on a screening approach of a discovery library, a series of benzoxazinepiperidinyl sulfonamides were identified as selective 5-HT<sub>6</sub> ligands. Many of the compds. described in this paper possess excellent affinities, displaying pK<sub>i</sub> values greater than 8 (some even >9) and high selectivities against a wide range (>50) of other CNS relevant receptors. First, structure-affinity relationships of these ligands are discussed. In terms of functionality, high-affinity antagonists, as well as agonists and even partial agonists, were prepared. Compds. 19c and 19g represent the highest-affinity 5-HT<sub>6</sub> agonists ever reported in the literature. These valuable tool compds. should allow for the detailed study of the role of the 5-HT<sub>6</sub> receptor in relevant animal models of disorders such as cognition deficits, depression, anxiety, or obesity.

IT 753020-88-1P 753020-89-2P 753020-90-5P


753020-91-6P 753020-93-8P

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(medicinal chemical driven approaches toward novel and selective serotonin 5-HT<sub>6</sub> receptor ligands)


RN 753020-88-1 CAPLUS

CN Imidazo[2,1-b]thiazole-5-sulfonamide, 6-chloro-N-[1-[2-(dimethylamino)ethyl]-1H-indol-6-yl]- (CA INDEX NAME)




RN 753020-89-2 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-6-yl]-3-methyl- (CA INDEX NAME)




RN 753020-90-5 CAPLUS

CN 1-Naphthalenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-6-yl]-  
(CA INDEX NAME)




RN 753020-91-6 CAPLUS

CN 2-Naphthalenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-6-yl]-  
(CA INDEX NAME)



RN 753020-93-8 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-N-[1-[2-(dimethylamino)ethyl]-2-methyl-1H-indol-6-yl]-3-methyl- (CA INDEX NAME)



REFERENCE COUNT:

68

THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

22.28

200.85

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.20

-3.20

STN INTERNATIONAL LOGOFF AT 12:10:33 ON 29 JUL 2008